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ABSTRACT
Mesenchymal stem cells (MSCs) have shown therapeutic promise in many experimental and
clinical models of inﬂammation. However, a commonly reported feature of MSC transplantation
is poor homing to injured tissues. Previously, we have shown that pretreatment with cytokines/
chemical factors enhances hematopoietic SC adhesion within intestinal microvasculature follow-
ing ischemia-reperfusion (IR) injury. Using intravital microscopy, the ability of similar pretreat-
ment strategies to enhance the recruitment of murine MSCs to murine intestinal
microvasculature following IR injury was investigated. Primary MSCs were isolated from bone
marrow and selected on the basis of platelet-derived growth factor receptor-a and SC antigen-1
positivity (PDGFRa1/Sca-11). MSC recruitment was similar in IR injured gut mucosa when com-
pared with sham operated controls, with limited cell adhesion observed. MSCs appeared con-
torted in microvessels, suggesting physical entrapment. Although not recruited speciﬁcally by
injury, MSC administration signiﬁcantly reduced neutrophil recruitment and improved tissue per-
fusion in the severely injured jejunum. Vasculoprotective effects were not demonstrated in the
lesser injured ileum. Pretreatment of MSCs with tumor necrosis factor (TNF)-a, CXCL12, inter-
feron (IFN)-c, or hydrogen peroxide did not enhance their intestinal recruitment. In fact, TNFa
and IFNc removed the previous therapeutic ability of transplanted MSCs to reduce neutrophil
inﬁltration and improve perfusion in the jejunum. We provide direct evidence that MSCs can
rapidly limit leukocyte recruitment and improve tissue perfusion following intestinal IR injury.
However, this study also highlights complexities associated with strategies to improve MSC ther-
apeutic efﬁcacy. Future studies using cytokine/chemical pretreatments to enhance MSC recruit-
ment/function require careful consideration and validation to ensure therapeutic function is not
impeded. STEM CELLS 2015;33:2785–2797
SIGNIFICANCE STATEMENT
Little is known about the in vivo kinetics of MSC homing to sites of injury, whether chemical
pre-treatments can modify this event and whether development of such strategies comes at
the cost of MSC functionality. In this study, we show that MSC adhesion within IR injured gut
mucosa is not only poor, but this phenomenon cannot be enhanced by pre-treatment with a
range of cytokines or chemical factors. However, despite limited homing, MSCs can confer an
anti-inflammatory effect and improve tissue perfusion in some anatomical regions of the gut.
However, this novel study highlights a serious consequence of MSC manipulation whereby their
therapeutic potential is demonstrated to be abolished following pre-treatment with particular
factors.
INTRODUCTION
Mesenchymal stem cells (MSCs) have rapidly
become one of the leading cell therapy candi-
dates for treating a variety of inﬂammatory
and degenerative diseases. Clinically, the pre-
ferred route of administration of stem cells
(SCs) for cellular therapy is by direct infusion
into the bloodstream, which provides a nonin-
vasive delivery method and allows repeated
injections of cells [1]. Capture of exogenously
administered circulating MSCs by injured tissue
microvascular endothelium is a prerequisite
event for successful therapy, regardless of the
mechanisms underlying MSC-mediated repair
[2]. Although most of our understanding of
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TISSUE-SPECIFIC STEM CELLS
MSC-endothelial interactions comes from in vitro research,
limited studies have investigated the actual kinetics of MSC
trafﬁcking in vivo at a cellular level. Injected MSCs have been
observed intravitally to adhere to healthy mouse ear veins,
albeit for short periods of time [3]. Vascular entrapment
rather than a dependency on active adhesion was further
shown as rat MSCs predominantly arrested in healthy cremas-
teric precapillaries, resulting in cessation of ﬂow in the
plugged microvessels [4]. In contrast, a recent study demon-
strated that active mechanisms, partially dependent on plate-
lets, were involved in governing human MSC adhesion and
transmigration within the lipopolysaccharide (LPS)-stimulated
inﬂamed ear dermis microcirculation [5].
These studies, conducted in vascular beds which are com-
monly used for intravital observations, provide a glimpse of
the kinetics of MSC recruitment in vivo. Since the therapeutic
potential of injected MSCs may be directly dependent on
their localization, it is anticipated that strategies which
enhance local recruitment will improve the effectiveness of
cellular therapy through acceleration of tissue recovery [2].
We have previously demonstrated that pretreatment of hema-
topoietic SCs (HSCs) with the reactive oxygen species hydro-
gen peroxide (H2O2) or the chemokine stromal derived factor-
1a (CXCL12) enhances their adhesion within the ischemia-
reperfusion (IR) injured gut [6, 7]. Nongenetically engineered
approaches to enhance HSC delivery offer the potential for
clinical use as an adjuvant therapy to increase the effectiveness
of HSC therapy. However, it is not known whether MSC recruit-
ment is also an event that can be improved using similar strat-
egies or whether recruitment mediated by injury alone is
maximal. Indeed, recent attention has focussed on MSCs pri-
marily due to their anti-inﬂammatory and immunomodulatory
effects observed in vitro and their low immunogenicity. How-
ever, direct evidence of vasculoprotection, and exactly what
this comprises, has not been demonstrated acutely in vivo in
the presence of disease or a clinically relevant injury.
In this study, we used intravital microscopy, a methodology
with single-cell sensitivity, to ﬁrst detail the kinetics of MSC
homing to IR injured mouse gut. This novel study directly exam-
ined MSC homing in a clinically relevant model of injury, which
has not previously been performed. MSC therapy has certainly
been proposed as a potential treatment for a whole host of
ischemic and inﬂammatory bowel disorders due to their ability
to dampen inﬂammation and promote tissue repair [8]. In mod-
els of colitis and autoimmune disease of the bowel, MSCs
improve a number of markers including diarrhea, body weight
and survival [9, 10]. Second, we assessed whether our previously
successful pretreatment strategies could enhance MSC adhesion
with the injured gut. Indeed, suboptimal MSC recruitment has
been proposed to explain the apparent differing results between
systemically and locally administered MSCs in models of Crohn’s
disease [11]. The ability of tumor necrosis factor (TNF)-a, H2O2,
CXCL12, and interferon (IFN)-c to modify MSC adhesion and
therapeutic potential was investigated. These factors were
selected based on their well-established roles in ischemia and
inﬂammation and their documented ability to manipulate the
therapeutic behavior of MSCs following administration in hosts
[12–15]. During IR injury, TNFa and H2O2 are released rapidly
into the local microenvironment with elevated and sustained
concentrations noted as early as the ﬁrst hour of reperfusion
[16, 17]. Intestinal IR injury is also associated with increased cir-
culating CXCL12 [18] and enhanced IFNc mRNA expression [19]
within 60 and 90 minutes post-reperfusion respectively.
Although the exact mechanisms that appear to underlie
the amelioration of injury by MSCs are unclear, they are
thought to involve paracrine release of anti-inﬂammatory
soluble factors, inhibition of proinﬂammatory lymphocytes,
and induction of T-cell apoptosis [20]. Whether MSCs exert
vasculoprotective effects while adherent within the microcir-
culation of damaged tissue, and how rapidly they do so, is
unclear [21, 22]. Therefore, the impact of naive or pretreated
MSCs on inﬂammatory neutrophil inﬁltration was also
assessed. The pathophysiology of IR injury is driven, in large,
by the activity of neutrophils; these are the major effector
cells. Neutrophils are among the ﬁrst cells to be recruited to
IR injured organs, where they release reactive oxygen species,
endothelial activators, and proteolytic enzymes. Given the
central role of the neutrophil in this injury, it was an appropri-
ate marker to examine the progression of IR injury. Improve-
ments in blood ﬂow to the IR injured gut were also
investigated as it is well known that IR injury compromises
local tissue perfusion. This is critical to assess as MSCs could
inadvertently impact negatively on blood ﬂow by plugging
microvessels and thus exacerbate the effects of ischemia.
MATERIALS AND METHODS
Animals
For both intravital microscopy and bone marrow isolation,
male C57Bl/6 mice (8–12 week old; Harlan, Oxon, UK) were
used for procedures in accordance with the Animals (Scientiﬁc
Procedures) Act of 1986. For intravital microscopy, anesthetized
animals (100 mg/kg ketamine hydrochloride, Zoetis UK, UK;
10 mg/kg xylazine hydrochloride, Chanelle Animal Health, UK;
intraperitoneally) underwent tracheotomy and carotid cannula-
tion to facilitate infusion of labeled cells and maintenance
anesthetic. IR injury was established through occlusion of the
small mesenteric artery using a nontraumatic artery clamp for
45 minutes. Reperfusion was initiated by clamp removal.
Cells
MSCs were isolated as described previously in detail elsewhere
[23]. Brieﬂy, muscle and surrounding tissue were removed
from the ﬁbulae and tibiae of 8–12 week adult male C57Bl/6
mice. Bones were fractured, marrow contents and remaining
bone fragments were incubated with 0.2% collagenase (Wako
Chemicals, Osaka, Japan) in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Sigma-Aldrich, Poole, UK). Cells were isolated
by mechanical dissociation from bone following incubation.
Subsequently, MSCs were selected from suspensions using ﬂow
cytometry (MoFlo XDP, Beckman Coulter, High Wycombe, UK).
Suspensions were labeled with FITC conjugated anti-mouse
Sca-1 (Ly6A/E; Clone D7, eBioscience, Hatﬁeld, UK), PE conju-
gated anti-mouse CD45 (30-F11; eBioscience, Hatﬁeld, UK), PE
conjugated anti-mouse TER-119 (Clone TER-119, eBioscience,
Hatﬁeld, UK), and APC conjugated anti-mouse CD140a
(PDGFRa; Clone APA5, eBioscience, Hatﬁeld, UK). Labeled sus-
pensions were washed and resuspended in Hanks’ balanced
saline solution (Sigma-Aldrich) with propidium iodide (eBio-
science, Hatﬁeld, UK). Cells were isolated based on positive
staining for Sca-1 and CD140a, along with negative staining for
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TER-119, CD45 and PI. This criteria yields an enriched popula-
tion of proliferative murine MSCs. Isolated cells were main-
tained in minimum essential medium a (MEMa) supplemented
with 10% fetal bovine serum (FBS; Sigma-Aldrich), L-glutamine
(PAA Laboratories, Yeovil, UK), penicillin/streptomycin (PAA), and
10 ng/ml transforming growth factor-b (TGFb; New England
Biolabs, Herts, UK). Cells were used for experiments between
passages 4 and 9. No correlation between passage number and
experimental results were identiﬁed within this range.
Surgical Preparation and Intravital Imaging
of the Ileum
Intravital microscopy was used to monitor MSC and neutro-
phil adhesion in injured intestinal microvasculature [7]. Since
the mucosal or luminal surface of the intestine is most sus-
ceptible to ischemic challenge, the mucosa of the distal ileum
was prepared for imaging by cautery incision alongside the
anti-mesenteric border. Exposed mucosal villi were visualized
using an inverted intravital microscope (Olympus IX-81, Olym-
pus, Essex, UK). For analysis, a single 310 ﬁeld of view was
selected before cell administration. 5 3 105 MSCs, prelabeled
with 10 lM 5,6-carboxyﬂuorescein diacetate succinimidyl ester
(CFDA-SE, Life Technologies, Paisley, UK), were injected intra-
arterially via the left common carotid at 30 minutes post-
reperfusion and recruitment in the mucosal villi analyzed. Cells
were administered at this time point to allow IR injury to be
established in the gut. Signiﬁcant intestinal microcirculatory
damage occurs at this point, associated with increased levels of
inﬂammatory factor release. This exposes trafﬁcking MSCs to
inﬂamed microvessels, providing them with an opportunity to
adhere rather than pass through the gut. Some MSCs were pre-
treated in a 1-ml suspension with 100 ng/ml TNFa (Peprotech,
London), 100 ng/ml interleukin (IL)21b (Peprotech, London),
100 ng/ml CXCL12 (Peprotech, London), or 100 mM H2O2
(Sigma-Aldrich) for 1 hour before their systemic administration.
Treatments were terminated by excess media and centrifuga-
tion. Pellets were resuspended in 100 ml of saline before infu-
sion. Digital videos were recorded for 1 minute, every 5
minutes, for an hour post-reperfusion. Adherent cells were iden-
tiﬁed as those that remained stationary for 30 seconds.
Images were also obtained post-mortem from the serosal sur-
face of the ileum, mucosal, and serosal surfaces of the proximal
jejunum, liver, spleen, and lungs. To monitor neutrophil recruit-
ment, mice were subjected to 45 minutes ischemia followed by
240 minutes reperfusion. Mice received an intra-arterial injec-
tion of 5 lg anti-mouse PE-Gr-1 antibody at 5 minutes and 235
minutes post-reperfusion (RB6–8C5; eBioscience, Hatﬁeld, UK).
This dose has been shown previously to efﬁciently label neutro-
phils while not altering functional behavior [24]. At 240 minutes
post-reperfusion, the mucosal villi of the more proximal jejunal
region of the small intestinal and the terminal ileum were pre-
pared for intravital imaging. Videos for analysis were obtained
from ﬁve regions in each anatomical area (ileum/jejunum). Data
were stored digitally and analyzed off-line (Slidebook, Intelligent
Imaging Innovations, Denver, CO, USA).
Blood Flow Analysis
Mucosal blood ﬂow was monitored using single channel laser
Doppler ﬂowmetry (moorVMS-LDF, Moor Instruments, Devon,
UK). Three ﬂux values were taken from independent areas in
either the jejunum or ileum. All data were normalized to pre-
ischemic ﬂux and presented as a ﬂux ratio.
Static Protein Substrate Adhesion Assay
The 96-well plates (Nunc, Rochester, NY, USA) were coated by
incubation with 10 lg/ml recombinant murine (rm) Intercellular
Adhesion Molecule 1 (rmICAM-1), 10 lg/ml vascular cell
adhesion protein 1 (rmVCAM-1), or 10 lg/ml mucosal vascular
addressin cell adhesion molecule 1 (rmMAdCAM-1) (R&D Sys-
tems, Abingdon, UK) at room temperature (RT) for 1 hour. Wells
were washed and the plate blocked using 10 mg/ml heat dena-
tured bovine serum albumin (BSA) (Sigma-Aldrich) at RT for 1
hour. MSCs were labeled with 10 lM CFDA-SE to enable visual-
ization. Subsequently, cells were pretreated with 100 lM H2O2,
100 ng/ml CXCL12, 100 ng/ml TNFa, or 100 ng/ml IFNc for one
hour. Wells were washed and pretreated MSCs were incubated
with coated plates for 20 minutes at RT. Following incubation,
cells were ﬁxed to proteins using 2% glutaraldehyde (Sigma-
Aldrich) for 15 minutes at 378C. Wells were washed and imaged
using an EVOS digital inverted ﬂuorescent microscope and GFP
light cube (both Life Technologies). Cell adhesion was quanti-
tated and expressed as a ratio against cell adhesion on BSA
following identical treatments.
Static Endothelial Cell Adhesion Assays
Immortalized colonic endothelial cells (ECs) were obtained as
described previously [25] from the Immortomouse (Charles
River, MA, US). ECs were expanded at 338C in MEM D-valine
(US Biological, TX, US), supplemented with 10% FBS (Sigma-
Aldrich), L-glutamine (Sigma-Aldrich), Penicillin/Streptomycin
(Sigma-Aldrich), 1% vitamin mix (Sigma-Aldrich), 1% nonessen-
tial amino acids (Sigma-Aldrich), and 10 U/ml IFNc (Pepro-
tech). ECs were cultured for experiments at 378C in DMEM
containing 10% FBS, L-glutamine and Penicillin/Streptomycin.
For experiments, ECs were grown to conﬂuence in gelatin-
coated 24 well plates (Nunc). To activate the endothelium,
100 ng/ml TNFa (Peprotech) was added at 378C for 4 hours.
MSCs were pretreated with 100 lM H2O2, 100 ng/ml CXCL12,
100 ng/ml TNFa, or 100 ng/ml IFNc for 1 hour. Following pre-
treatment, MSCs were incubated with ECs at 378C for 20
minutes. Nonadherent cells were washed and wells were ﬁxed
with 10% formalin for 15 minutes at 378C and imaged using
an EVOS FL digital-inverted ﬂuorescent microscope.
Enzyme Linked Immunosorbent Assay
The release of potentially active factors (both pro- and anti-
inﬂammatory) from MSCs was tested using commercially avail-
able ELISAs (eBioscience, Hatﬁeld, UK). PDGFRa1 MSCs were
grown to 90% conﬂuence in 24-well plates. MSCs were subse-
quently treated for 24 hours with either 100 ng/ml TNFa, 100
ng/ml IFNc, 100 ng/ml CXCL12, or 100 mM H2O2 and their super-
natants obtained. These supernatants were analyzed by ELISA
for IL-1b, TNF-a, IL-10, IL-13, and IL-6. Assays were performed
according to manufacturer’s instructions. Dynamics of IL-6
release was examined in detail following treatment with 100 ng/
ml TNFa or 100 ng/ml IFNc. After treatment for 1 hour, superna-
tant was removed and labeled H1. The same MSCs were treated
further for an additional hour in aMEM containing 100 ng/m
TNFa or 100 ng/ml IFNc. This supernatant was isolated, labeled
H2 and fresh media containing TNFa or IFNc added. This
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culturing routine continued for 5 hours (sample H5). Superna-
tants were ﬁltered and stored at 2208C until analyzed.
Statistical Analysis
Intravital microscopy and laser Doppler data were ana-
lyzed by two-way analysis of variance (ANOVA) followed
by comparison corrected post-tests to identify points of
signiﬁcance. Other multiple comparisons were analyzed by
one-way ANOVA followed by comparison corrected post-
hoc tests. Direct comparison of two groups was per-
formed by unpaired Student’s t-test. Data are presented
as mean6 SEM.
Figure 1. Mesenchymal stem cells (MSCs) are not recruited speciﬁcally as a result of injury and appear contorted in the vasculature.
(A): MSC recruitment to ischemia-reperfusion (IR) injured ileum was not signiﬁcantly enhanced compared with sham operated controls
(mean cells adherent/ﬁeld6 SEM; n 5). (B): MSC recruitment was not enhanced in other tissues as a result of intestinal IR when com-
pared with sham controls (mean cells/ﬁeld6 SEM; n 5). (C): Representative images are shown of MSCs present in the lumenal mucosa
and outer serosal wall following sham or IR injury. MSCs appeared elongated and contorted primarily in the serosal microcirculation
(white arrows). (D): Occassionally, MSCs were observed appearing to “release” intracellular contents into the microvasculature. Abbrevi-
ation: IR, ischemia-reperfusion.
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RESULTS
Increased Adhesion of Primary PDGFRa1 MSCs Is Not
Observed Following Intestinal IR Injury
MSC adhesion within the mucosal microcirculation of the
ileum was not enhanced in IR injured animals and was no dif-
ferent to that observed in sham mice (Fig. 1A, 1C). Indeed,
numbers of adherent cells were low (between 2 and 4 cells
per ﬁeld of view) in both sham and injured mice, albeit
increasing gradually over the course of the experiment. Adhe-
sion was primarily “ﬁrst pass”; few MSCs were observed traf-
ﬁcking through the intestine during the remainder of the
experiment. Microscopic post-mortem examination of addi-
tional sites in the intestine and other organs revealed that
recruitment was not enhanced in remote organs as a result of
intestinal injury (Fig. 1B). Unsurprisingly, the highest presence
of cells was observed in the pulmonary capillaries in both
sham and injured mice (Fig. 1B). The majority of adherent SCs
in the mucosal microcirculation appeared smaller and
rounded in shape, in contrast to those in the outer serosal
layer where MSCs primarily displayed an elongated and more
contorted shape. These appearances were characteristic of
vascular plugging by MSCs (Fig. 1C). Interestingly, MSCs adher-
ent within the mucosal microcirculation of injured mice occa-
sionally appeared to spontaneously release contents,
evidenced by extrusion of ﬂuorescent content and then
decreasing in size (Fig. 1D).
MSCs Reduce Neutrophil Recruitment and Improve
Tissue Blood Flow in IR Injured Jejunum
Our previous observations identiﬁed that intestinal IR injury
was associated with a difference in the degree of macroscopic
injury in the proximal jejunum and the terminal ileum, with
the former appearing hemorrhagic, severely congested and
swollen [26]. As varying macroscopic injury occurs in these
regions, both were assessed to determine whether blood ﬂow
and neutrophil adhesion could be modiﬁed by local MSC pres-
ence. First, we showed that ileal blood ﬂow was signiﬁcantly
reduced following IR injury when compared with sham blood
ﬂow and failed to reach preischemic levels (e.g., normalized
ﬂux at 240 minutes post reperfusion: sham: 0.856 0.07 vs.
IR: 0.406 0.07; p< 0.01; Fig. 2A). Although ileal blood ﬂow
appeared to be improved in IR injured mice receiving MSCs,
this difference was not signiﬁcant when compared with mice
not receiving MSCs (Fig. 2B). Neutrophil adhesion in IR injured
ileal mucosa was signiﬁcantly higher than that identiﬁed in
sham controls (adherent neutrophils/ﬁeld: control: 9.06 1.0
vs. IR: 23.86 3.9; p< 0.05) and was not reduced by the
administration of MSCs (Fig. 2C, 3).
Tissue blood ﬂow in the jejunum was also signiﬁcantly
reduced following IR injury and, similarly to the ileum, failed
to restore to preischemic levels (e.g., normalized ﬂux at 240
minutes post reperfusion: sham: 0.876 0.07 vs. IR:
0.506 0.10; p< 0.01; Fig. 2D). However, blood ﬂow was sig-
niﬁcantly improved at 60 minutes post-reperfusion in mice
receiving MSCs (normalized ﬂux at 60 minutes reperfusion: IR:
0.496 0.05 vs. IR1MSCs: 0.976 0.13; p< 0.05; Fig. 2E). This
beneﬁcial effect was transient and not observed at 4 hours
post-reperfusion (normalized ﬂux at 240 minutes reperfusion:
IR: 0.506 0.10 vs. IR1MSC: 0.616 0.13). Neutrophil adhe-
sion in IR injured jejunum was also signiﬁcantly increased
when compared with sham controls (adherent neutrophils/
ﬁeld: control: 3.86 1.3 vs. IR: 54.46 14.2; p< 0.01; Figs. 2F,
3). The greater susceptibility of the jejunum to injury was fur-
ther reﬂected by higher levels of neutrophils adherent within
IR injured jejunal mucosal microcirculation (54.46 14.2;
>143 that in shams) compared with the ileum (23.86 3.9;
>2.53 that in sham). However, in the jejunum, neutrophil
recruitment was signiﬁcantly reduced in IR mice receiving
MSCs (adherent neutrophils/ﬁeld: IR: 54.46 14.2 vs.
IR1MSCs: 13.06 3.6; p< 0.01; Fig. 2F).
Pretreatment of MSCs Did Not Enhance Their
Adhesion
Pretreatment of MSCs with CXCL12, H2O2, TNFa, or IFNc did
not enhance their adhesion to immobilized endothelial ligands
ICAM-1, VCAM-1, or MAdCAM-1 (Fig. 4A) or to murine colonic
endothelium (Fig. 4B) when assessed using static in vitro
adhesion assays. Similarly, no pretreatment strategy increased
MSC adhesion in vivo in the ileum following IR injury or in
any additional organs when compared with phosphate-
buffered saline (PBS)-treated control cells (Fig. 4C–4J).
TNFa and IFNc Pretreatment Elicits a Rapid Release of
IL-6 from MSCs
MSCs were treated with 100 ng/ml CXCL12, 100 mM H2O2,
100 ng/ml TNFa, or 100 ng/ml IFNc for 24 hours and the
resulting supernatant was analyzed using ELISAs for pro- and
anti-inﬂammatory factors. IL-10, IL-13, IL-1b, and TNFa release
was not detected with any of the pretreatment strategies
(data not shown). However, both TNFa and IFNc pretreatment
induced signiﬁcant release of IL-6 into the supernatant (PBS:
15.26 6.7 g/ml; TNFa: 272.36 25.03 pg/ml (p< 0.001 vs.
PBS); and IFNc: 108.96 26.1 pg/ml (p< 0.01 vs. PBS); Fig.
5A). The dynamics of IL-6 with these two pretreatments was
further examined in detail. Upon stimulation with TNFa, signif-
icant levels of IL-6 were released that peaked at 2 hours, that
is, in sample H2, with decreasing but signiﬁcant detection
observed thereafter in H3 and H4 samples (Fig. 5B). The pat-
tern of IL-6 release, although broadly similar with IFNc, was
generally lower than release induced by TNFa, and only signif-
icantly raised at H2 (Fig. 5C).
Pretreatment of MSCs with TNFa Abolishes Their
Vasculoprotective Effects In Vivo
Having demonstrated that TNFa and IFNc were most potent
at stimulating release of IL-6 from MSCs, their ability to elicit
anti-inﬂammatory and vasculoprotective effects in the ileum
and jejunum in vivo was assessed intravitally. Administration
of TNFa prestimulated MSCs did not improve ileal tissue
blood ﬂow when compared with mice receiving nonstimulated
MSCs (Fig. 6A). No reduction in neutrophil adhesion was
observed in the ileum at 4 hours post-reperfusion (Fig. 6B).
As shown previously, administration of unstimulated MSCs
improved blood ﬂow at early time points in the severely dam-
aged jejunum and signiﬁcantly reduced neutrophil adhesion
(Fig. 3F, 3G). However, this previously vasculoprotective effect
was lost when TNFa-stimulated MSCs were used (Fig. 6C, 6D).
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Pretreatment of MSCs with IFNc Either Renders MSCs
Vasculoprotective in Areas of Limited Injury or
Abolishes This Effect in Severely Damaged Areas
In Vivo
Administration of IFNc-stimulated MSCs did not improve ileal
tissue blood ﬂow compared with mice receiving nonstimu-
lated MSCs (Fig. 7A). As shown earlier, administration of unsti-
mulated MSCs did not reduce neutrophil adhesion in the IR
injured ileum (Fig. 6B). However, administration of IFNc-
stimulated MSCs signiﬁcantly (p< 0.05) reduced neutrophil
recruitment in the lesser injured ileum following IR injury (Fig.
7B). Again the previously vasculoprotective effects of
Figure 2. Mesenchymal stem cells (MSCs) improve tissue blood ﬂow and reduce neutrophil recruitment in the severely injured jeju-
num. (A): Blood ﬂow, as measured by laser Doppler, was signiﬁcantly reduced following ischemia-reperfusion (IR) injury when compared
with sham mice (IR1 S: IR injury with saline bolus; results represent normalized ﬂux6 SEM; n 5). (B): Blood ﬂow was not signiﬁcantly
improved in the ileum by administration of MSCs when compared with saline treated controls (normalized ﬂux6 SEM; n5 6). (C): Neu-
trophil recruitment was signiﬁcantly increased in the ileum following IR injury. Administration of MSCs did not reduce neutrophil recruit-
ment following IR (mean adherent neutrophils/ﬁeld6 SEM; n5 5). (D): Blood ﬂow was signiﬁcantly reduced in the jejunum following IR
injury when compared with sham controls (normalized ﬂux6 SEM; n5 6). (E): Jejunal blood ﬂow was signiﬁcantly improved at the
earliest timepoint in mice receiving MSCs (normalized ﬂux6 SEM; n5 6). (F): Neutrophil recruitment was increased in the jejunum
following IR injury with MSCs downregulating their adhesion (mean adherent neutrophils/ﬁeld6 SEM; n5 5). Abbreviations: IR,
ischemia-reperfusion, MSC, mesenchymal stem cell.
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unstimulated MSCs in the injured jejunum was lost when
IFNc-stimulated MSCs were used (Fig. 7C, 7D).
DISCUSSION
Cell-based therapies, including those using MSCs, are limited
by inefﬁcient homing and capture of cells by injured tissue
microcirculation. Therefore, it is accepted that enhancing their
adhesion following systemic delivery may improve therapeutic
efﬁcacy. However, no studies have directly tracked the homing
of MSCs within a clinically relevant model of injury at a cellu-
lar level. Furthermore, the acute effects of MSCs within their
immediate vascular environment, which may mechanistically
explain their potential therapeutic efﬁcacy, have not been
directly monitored. In this study, we provide evidence that
very few injected MSCs actually home to and are retained
within IR injured gut mucosa, with no differences observed
between healthy and injured tissue. This is in contrast to our
extensive studies on HSCs in which a four- to ﬁvefold higher
number of adherent cells were observed within a similarly
injured organ [7, 27]. MSC adhesion was not enhanced using
pretreatment strategies shown previously by us and others to
increase HSC adhesion. However, despite this, vasculoprotec-
tion was afforded by recruited MSCs, but this was dependent
on the severity of the injury and degree of inﬂammation.
What was most striking was the observation that pretreat-
ment strategies rendered potentially therapeutic cells rela-
tively incompetent. This clearly has important consequences
when designing protocols for clinical translation, particularly
in the context of intestinal IR injury.
Although MSC homing has been assessed using various
noninvasive techniques, including whole animal IVIS, x-ray,
ultrasound and MRI, these methods do not have single cell
resolution. Therefore, the actual number of SCs homing is
likely underestimated or unidentiﬁed. Our more sensitive
approach demonstrated that limited cells freely circulated
through the mucosal microcirculation and of these, few
became adherent. This lack of a ﬁrm interaction with mucosal
endothelium may be due to large MSCs (up to 25 lm [28])
becoming trapped upstream before entering the small diame-
ter mucosal capillaries (9–12 lm [29]). This was evidenced by
the striking appearance of elongated MSCs observed in the
outer wall serosal microvessels. Indeed, a number of distorted
MSCs were frequently observed to line the length of a serosal
microvessel. The phenotype of the MSCs in the serosa also
suggests only smaller or possibly more deformable MSCs
were delivered to the mucosa, as evidenced by the round
physical phenotype of cells identiﬁed in this region. Work by
Toma and colleagues also illustrated the difﬁculty faced by
large MSCs trafﬁcking through microvessels [4]. They noted
microvascular plugging in cremaster muscle following MSC
transplantation. Interestingly, the authors also noted that
while mononuclear cells (MNCs) could migrate through mem-
branes with a pore size of 5 lm, MSCs struggled to migrate
through pores of 10 lm [4] This did not appear to be due to
poor deformability of MSCs as the authors provided evidence
that MSCs and MNCs were equally deformable, leading them
to suggest that MSC entrapment was primarily a factor of
their physical size [4]
The lack of circulating MSCs entering the intestinal
mucosa is further compounded by the anatomy of the gut
wall vasculature. Mesenteric vessels enter the intestine via
the outer serosa with parallel branches supplying the serosa,
muscle, and submucosal layers. Each mucosal villus is supplied
by a central arteriole which originates at right angles to the
parent submucosal arteriole. Although the majority of cellular
components including neutrophils within the submucosal arte-
riole continue to the mucosa, this angle would make it difﬁ-
cult for large MSCs to gain similar access. Although decreasing
Figure 3. Neutrophil recruitment following ischemia-reperfusion (IR) injury with or without administration of mesenchymal stem cells
(MSCs). Neutrophils were labeled in vivo and their recruitment monitored in the microvasculature. Representative images are shown of
the ileal and jejunal mucosa of mice following sham injury, IR injury with a saline bolus (IR1 Saline) or IR injury with administration of
MSCs (IR1MSC). Abbreviations: IR, ischemia-reperfusion, MSC, mesenchymal stem cell.
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Figure 4. Pretreatment of mesenchymal stem cells (MSCs) with CXCL12, hydrogen peroxide (H2O2), tumor necrosis factor (TNF)-a, or
interferon (IFN)-c did not enhance MSC adhesion both in vitro and in vivo. (A): Treatment of MSCs with a variety of agents did not
enhance their ability to adhere to the immobilized protein substrates ICAM-1, VCAM-1, or MAdCAM-1. (B): Similarly, MSC adhesion to
murine colonic endothelium was not enhanced by pretreatment. Interestingly, MSC adhesion was not dependent on the activation state
of the endothelium. (C, E, G, I): Treatment of MSCs with CXCL12, H2O2, TNFa, or IFNc did not signiﬁcantly enhance their recruitment in
the ileum following ischemia-reperfusion (IR) injury. (D, F, H, J): Additionally, pretreatment of MSCs did not affect their tissue distribu-
tion in the IR mouse following administration. Abbreviations: H2O2, hydrogen peroxide; ICAM, Intercellular Adhesion Molecule 1; IFN-c,
interferon-c; MAdCAM-1, mucosal vascular addressin cell adhesion molecule 1; PBS, phosphate-buffered saline; TNF-a, tumor necrosis
factor-a; VCAM, vascular cell adhesion protein 1.
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blood ﬂow rates, or even stopping ﬂow completely, has been
shown to be conducive (if not necessary) for MSC adhesion in
vitro [30, 31], no increased adhesion was observed in vivo
despite a decrease in mucosal blood ﬂow in the IR injured
gut. Reducing blood ﬂow may mean less MSCs are delivered
to injured tissue. However, we have previously demonstrated
that HSCs (and indeed inﬂammatory leukocytes) are able to
adhere in increased number despite a reduction in intestinal
blood ﬂow. It is also possible that vasoconstriction in serosal
arterioles post-reperfusion at the time of MSC infusion may
limit or restrict the ease with which injected MSCs can ﬂow
to the mucosa [32].
It is difﬁcult to say deﬁnitively that intestinal MSC recruit-
ment is driven purely by their size. Although physical entrap-
ment is certainly a major mechanism governing local MSC
presence, active mechanisms may also be involved as MSCs
express a wide range of adhesion molecules (L-selectin, CD44,
CD49a-f, CD29, CD18, among others) which have been shown
to be important in MSC homing [21, 22]. Indeed, we have
previously shown that if MSC adhesion increases with injury,
for example, in the liver, integrins and nonintegrins can medi-
ate their recruitment [30]. Given that adhesion in our model
was not increased following injury, we propose that the pres-
ence of MSCs in the injured intestine is mediated (at least pri-
marily) by passive entrapment and that active, molecular
driven recruitment may not play a signiﬁcant role in this
model. This is in contrast to our previous studies in which
enhanced active HSC recruitment was observed in the gut fol-
lowing a similar IR injury [7]. HSCs are much smaller, with
primitive HSCs possessing diameters of around 9.5 mm [33].
As such, they can most likely circulate relatively unhindered
through the intestinal microcirculation, making frequent inter-
actions with inﬂamed endothelium. This increases the likeli-
hood of ﬁrm HSC-endothelial interactions taking place, which
may explain why an increased HSC presence is observed in IR
injured gut compared with sham. In addition, preliminary
atomic force microscopy studies in our laboratory suggest
MSCs are signiﬁcantly less deformable than HSCs, when com-
paring biomechanical properties such as rupture forces
(Du M, unpublished observations).
Despite small numbers of MSCs being recruited to
injured mucosa, signiﬁcant down regulation of neutrophil
recruitment and improvements in tissue perfusion were
observed. This is the ﬁrst study to directly demonstrate and
specify the vasculoprotective effects that MSCs can confer in
vivo and the speed at which these events take place post-
MSC infusion. Interestingly, the capacity for MSCs to attenu-
ate injury varied between different anatomical regions of the
intestine and appeared to be dependent on the degree of
injury. Grossly visible damage was apparent in the jejunum,
with neutrophil adhesion more than doubled in this region
compared with the ileum. Varying susceptibility of the gut to
IR injury has been described previously by us [26] and also
Chan et al., who demonstrated that basal levels of protective
nitric oxide (NO) were higher in the rat ileum than the jeju-
num [34, 35]. Also, the release of protective peptides follow-
ing IR injury is signiﬁcantly higher in the ileum when
compared with the jejunum [36]. It is interesting that the
therapeutic vasculoprotective effects of MSCs were observed
in the more damaged jejunum rather than the lesser injured
ileum. This suggests circulating MSCs may require high
Figure 5. Mesenchymal stem cells (MSCs) rapidly release
interleukin (IL)26 following stimulation with tumor necrosis
factor (TNF)-a or interferon (IFN)-c. (A): MSCs release IL-6 fol-
lowing 24 hours treatment with TNFa or IFNc, but not
CXCL12 or hydrogen peroxide (mean [IL-6], pg/ml6 SEM;
n5 4). (B): The supernatants of TNFa stimulated MSCs were
isolated and examined at hourly intervals; the media used to
replace the isolated supernatants contained fresh TNFa.
Release of IL-6 begins early and peaks in sample H2, which
represents the second hour of MSC treatment with TNFa
(mean [IL-6]6 SEM; n5 3). (C): Similarly, following treatment
with IFNc, IL-6 release peaks in sample H2 (mean
[IL-6]6 SEM; n5 3). For panels (B) and (C), *, versus
untreated; 1, versus H1; D, versus H2; •, versus H3; x, versus
H4. Abbreviations: IFN-c, interferon-c; IL-6, interleukin-6;
PBS, phosphate-buffered saline; TNF-a, tumor necrosis
factor-a.
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concentrations of inﬂammatory mediators or chemical stress
signals to be present locally before they “switch on” protec-
tive mechanisms. Interestingly, the occasional intravital
images of MSCs appearing to “release” their cytoplasmic
content within the injured mucosa were mostly captured in
the jejunum. Adherent neutrophils can contribute to vascular
congestion and no-reﬂow—hence dampening the neutrophil
inﬁltrate may explain the resumption of tissue perfusion and
early improvements in jejunal blood ﬂow. MSCs are also well
known for their ability to secrete biologically signiﬁcant
amounts of NO, driven by inducible nitric oxide synthase
(iNOS) [37]. Previous studies have shown that upregulation
of iNOS mRNA does not occur until around 2–4 hours post
activation [37]. If MSC-derived NO is mediating improve-
ments in vascular tone following IR injury, this effect would
likely be observed at later time points, as seen in the ileum
in this study.
It is interesting that despite poor MSC presence, neutro-
phil inﬁltration was modiﬁed. It may be possible that high lev-
els of local MSC recruitment are not required in order to
realize their therapeutic beneﬁt. MSCs are potent anti-
inﬂammatory cells and as such the level of MSC recruitment
required for therapeutic function may be met with the
observed basal recruitment. Alternatively, the localization of
MSCs may not be critically important for inducing therapeutic
activity. There is growing experimental data supporting the
idea that, after intravenous injection, MSCs interact with
immunologic cells located in distant organs (primarily the
lungs) thereby altering the systemic immunologic/inﬂamma-
tory response. Indeed, MSCs located in the pulmonary micro-
vasculature are able to secrete factors which improve
outcomes in other tissues, such as the heart and the brain
[38–40]. Such results indicate that it may not be necessary
for a large number of cells to reach the injured tissue to pro-
duce an effect.
We previously demonstrated that HSC pretreatment with
soluble inﬂammatory factors enhanced their adhesion within
IR injured gut. Such pretreatments modiﬁed adhesion either
by enhancing integrin clustering on HSCs and/or increasing
their afﬁnity/avidity for endothelial counterligands. Cytokine
treatment of MSCs has also been shown previously to upregu-
late adhesion molecule expression on their surface [41]. How-
ever, in this study, these pretreatment strategies did not
improve MSC adhesion. This suggests MSC recruitment may
not be an active process or reﬂect poor upregulation of adhe-
sion molecules on PDGFRa1 murine MSCs. In light of our data
suggesting MSC recruitment is mediated primarily by physical
entrapment, we postulated that our chemical prestimulations
would improve adhesion through effects on deformability or
other physical characteristics that may inﬂuence cell entrap-
ment. Indeed, HSC deformability increases with factors such
as CXCL12, preventing nonspeciﬁc entrapment in sites such as
the lungs and thus maintaining a larger pool of circulating
cells in the peripheral blood [42]. We did not note changes in
Figure 6. Pretreatment of mesenchymal stem cells (MSCs) with TNFa abolishes their vasculoprotective effects in vivo. (A): Administra-
tion of tumor necrosis factor (TNF)-a treated MSCs did not improve ileal blood ﬂow following ischemia-reperfusion (IR) injury (normal-
ized ﬂux6 SEM, n 4). (B): Administration of TNFa treated MSCs did not reduce neutrophil recruitment in the ileum following IR injury
when compared with mice receiving a saline bolus (mean adherent neutrophils/ﬁeld6 SEM; n5 5). (C): Similarly, administration of
TNFa treated MSCs did not improve jejunal blood ﬂow following IR injury (normalized ﬂux6 SEM, n 4). (D): Administration of TNFa
treated MSCs did not reduce neutrophil recruitment in the jejunum following IR injury when compared with mice receiving a saline
bolus (mean adherent neutrophils/ﬁeld6 SEM; n5 5). Abbreviations: IR, ischemia-reperfusion, MSC, mesenchymal stem cell; TNF-a,
tumor necrosis factor-a.
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recruitment in vivo following stimulation of cells with these
treatments. It is known that oxidative stress (H2O2) can lead
to increased cell stiffness of MSCs [4]. This may exacerbate
the problem of cell entrapment and thus explain the lack of
enhanced adhesion in the gut. Indeed, in this study, H2O2 pre-
treatment was noted to increase MSC presence, albeit non-
signiﬁcantly, in the lungs.
Interestingly, it is possible that MSC recruitment in vivo is
inhibited in platelet-featuring pathologies. Platelets play an
important pathological role in many ischemic disorders.
Indeed, following intestinal IR injury platelet recruitment
begins as early as 5 minutes post-reperfusion [43]. Recent
work by Vogel et al. demonstrated that conditioned media
derived from activated platelets strongly inhibited MSC migra-
tion towards injured cardiomyocytes in vitro [44]. However,
our static adhesion assays also showed no increase in MSC
adhesion to platelet-free, immobilized endothelial ligands
ICAM-1, VCAM-1, and MAdCAM-1 following any pretreatment.
In addition, MSC adhesion was not enhanced to activated
endothelium either. Collectively, this data suggest that MSCs
may be poorly adhesive and as such, any effects of stimula-
tions before administration may not be sufﬁcient to enhance
their recruitment when administered in vivo.
Although no modiﬁcation of MSC adhesion was observed,
preexposure of MSCs to inﬂammatory mediators may potenti-
ate the release of paracrine factors. Thus, pretreatment may
render MSCs of greater therapeutic beneﬁt. Indeed, evidence
suggests that the immunosuppressive potency of MSCs is
greatly increased when prestimulated with IFNc [45]. Further-
more, pretreatment with IL-1b has been shown to enhance
the therapeutic efﬁcacy of MSC transplantation in a mouse
model of colitis, when compared with naive cells [46]. We
ﬁrst tested whether pretreatment could stimulate release of
potentially beneﬁcial anti-inﬂammatory factors, namely IL-10,
IL-13, and IL-6, from primary PDGFR1 MSCs. Release of proin-
ﬂammatory IL-1b and TNFa, was also tested. Signiﬁcant
increases in IL-6 were detected following pretreatment with
TNFa and IFNc. Cellular release of IL-6 peaked at 2 hours
post-stimulation with decreased IL-6 release detected there-
after. Although MSCs express the receptors TNFR1, TNFR2,
and IFNcR1, our data suggest that these receptors may be
engaged in activities that modulate cytokine release rather
than the adhesive capabilities of MSCs. The potential impor-
tance of IL-6 as a beneﬁcial paracrine factor released from
MSCs is given signiﬁcance in light of evidence that it can limit
warm hepatic IR injury through down regulation of TNFa
release [47]. IL-6 has also been shown to drive release of sec-
ondary mediators such as prostaglandin E2 (PGE2) [48]. Fur-
thermore, exogenously administered IL-6 has also been shown
to protect the inner retina after IR injury [49]. Future studies
could address the possibility of administering IL-6 as an adju-
vant to maximise the efﬁcacy cellular therapy.
As TNFa and IFNc were most effective at stimulating IL-6
release from MSCs at 2 hours, we further tested for enhanced
Figure 7. Pretreatment of mesenchymal stem cells (MSCs) with interferon (IFN)-c renders MSCs vasculoprotective in areas of limited
injury. (A): Administration of interferon (IFN)-c treated MSCs did not improve ileal blood ﬂow following ischemia-reperfusion (IR) injury
(normalized ﬂux6 SEM, n 4). (B): Administration of IFNc-treated MSCs reduced neutrophil recruitment in the ileum following IR injury
when compared with mice receiving a saline bolus (mean adherent neutrophils/ﬁeld6 SEM; n5 5). (C): Similarly, administration of IFNc
treated MSCs did not improve jejunal blood ﬂow following IR injury (normalized ﬂux6 SEM, n 4). (D): Administration of IFNc treated
MSCs did not reduce neutrophil recruitment in the jejunum following IR injury when compared with mice receiving a saline bolus
(mean adherent neutrophils/ﬁeld6 SEM; n5 5). Abbreviations: IFN-c, interferon-c; IR, ischemia-reperfusion, MSC, mesenchymal stem
cell.
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therapeutic efﬁcacy of these pretreated cells in vivo. Again,
improvements in mucosal blood ﬂow and down regulation of
neutrophil adhesion were investigated compared with vehicle
treated MSCs. MSCs were stimulated with TNFa or IFNc for 1
hour and then systemically introduced into IR injured mice.
Surprisingly, pretreated cells failed to confer the vasculopro-
tective effects previously observed by naive MSCs in the jeju-
num. However, in contrast, previously nontherapeutic MSCs
decreased ileal neutrophil adhesion when IFNc treated. Collec-
tively this suggests pretreatment abolishes the MSC vasculo-
protective effects in areas of severe tissue injury, but may
render them vasculoprotective in regions of limited tissue
injury. The undermining of previously beneﬁcial MSCs in the
jejunum may be due to a shift towards earlier “peak release”
of paracrine mediators. Maximal IL-6 release was noted at 2
hours post-stimulation yet IR injury becomes progressively
worse with time. It is also possible that IFNc (but not TNFa)
may cause the release of an unknown factor that is able to
reduce neutrophil recruitment in the lesser injured ileum.
Alternatively, given that less IL-6 was secreted in vitro with
IFNc compared with TNFa, MSCs may not have been
“depleted” to the same degree before having a chance to
confer an anti-inﬂammatory action in the ileum. Clearly a cen-
tral role for MSC-derived IL-6 is apparent as it has been dem-
onstrated in a number of studies to limit local release of
proinﬂammatory mediators. In a model of carbon tetrachlor-
ide (CCl4) induced hepatic injury, evidence suggests IL-6 plays
an important role in ameliorating hepatic injury by MSCs [50].
In a model of LPS-induced pulmonary injury, IL-6 mediates the
protective effects of adipose derived MSCs (ASCs) [51].
CONCLUSION
In conclusion, our data show that limited MSCs home success-
fully to the injured gut mucosa, an event that we could not
improve. However, despite this, MSCs were vasculoprotective
in that they were able to downregulate neutrophil adhesion
and improve blood ﬂow. For the ﬁrst time, we show that the
severity of injury, even in the same organ, impacted on the
therapeutic efﬁcacy of MSCs. Furthermore, stimulation of
MSCs before administration may not always be beneﬁcial and
may in some scenarios hinder the ability of these cells to per-
form their anti-inﬂammatory functions. With the number of
clinical trials involving MSCs increasing, this current data sug-
gest that pretreatment strategies should be carefully consid-
ered and validated before use. Although there is an urgency
to identify strategies that promote MSC recruitment to sites
of injury, it is equally important to identify and rule out those
strategies that do may negatively impact on their therapeutic
potential. In this study, cytokine pretreatment presents itself
as a double-edged sword whereby the beneﬁts in the lesser
injured regions of the gut may be offset by loss of beneﬁt in
the severely injured gut.
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